Synergy between loss of NF1 and overexpression of MYCN in neuroblastoma is mediated by the GAP-related domain

Shuning He, Marc R. Mansour, Mark W. Zimmerman, Dong Hyuk Ki, Hillary M. Layden, Koshi Akahane, Evisa Gjini, Eric D. de Groh, Antonio R. Perez-Atayde, Shizhen Zhu, Jonathan A. Epstein, A. Thomas Look

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Earlier reports showed that hyperplasia of sympathoadrenal cell precursors during embryogenesis in Nf1-deficient mice is independent of Nf1‘s role in down-modulating RAS-MAPK signaling. We demonstrate in zebrafish that nf1 loss leads to aberrant activation of RAS signaling in MYCN-induced neuroblastomas that arise in these precursors, and that the GTPase-activating protein (GAP)-related domain (GRD) is sufficient to suppress the acceleration of neuroblastoma in nf1-deficient fish, but not the hypertrophy of sympathoadrenal cells in nf1 mutant embryos. Thus, even though neuroblastoma is a classical "developmental tumor", NF1 relies on a very different mechanism to suppress malignant transformation than it does to modulate normal neural crest cell growth. We also show marked synergy in tumor cell killing between MEK inhibitors (trametinib) and retinoids (isotretinoin) in primary nf1a-/- zebrafish neuroblastomas. Thus, our model system has considerable translational potential for investigating new strategies to improve the treatment of very high-risk neuroblastomas with aberrant RAS-MAPK activation.

Original languageEnglish (US)
Article numbere14713
JournaleLife
Volume5
Issue numberAPRIL2016
DOIs
StatePublished - Apr 27 2016

Fingerprint

GTPase-Activating Proteins
Neuroblastoma
Tumors
Chemical activation
Isotretinoin
Mitogen-Activated Protein Kinase Kinases
Retinoids
Cell growth
Fish
Zebrafish
Cells
Neural Crest
Hypertrophy
Embryonic Development
Hyperplasia
Neoplasms
Fishes
Embryonic Structures
Protein Domains
Growth

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)
  • Neuroscience(all)

Cite this

He, S., Mansour, M. R., Zimmerman, M. W., Ki, D. H., Layden, H. M., Akahane, K., ... Thomas Look, A. (2016). Synergy between loss of NF1 and overexpression of MYCN in neuroblastoma is mediated by the GAP-related domain. eLife, 5(APRIL2016), [e14713]. https://doi.org/10.7554/eLife.14713

Synergy between loss of NF1 and overexpression of MYCN in neuroblastoma is mediated by the GAP-related domain. / He, Shuning; Mansour, Marc R.; Zimmerman, Mark W.; Ki, Dong Hyuk; Layden, Hillary M.; Akahane, Koshi; Gjini, Evisa; de Groh, Eric D.; Perez-Atayde, Antonio R.; Zhu, Shizhen; Epstein, Jonathan A.; Thomas Look, A.

In: eLife, Vol. 5, No. APRIL2016, e14713, 27.04.2016.

Research output: Contribution to journalArticle

He, S, Mansour, MR, Zimmerman, MW, Ki, DH, Layden, HM, Akahane, K, Gjini, E, de Groh, ED, Perez-Atayde, AR, Zhu, S, Epstein, JA & Thomas Look, A 2016, 'Synergy between loss of NF1 and overexpression of MYCN in neuroblastoma is mediated by the GAP-related domain', eLife, vol. 5, no. APRIL2016, e14713. https://doi.org/10.7554/eLife.14713
He S, Mansour MR, Zimmerman MW, Ki DH, Layden HM, Akahane K et al. Synergy between loss of NF1 and overexpression of MYCN in neuroblastoma is mediated by the GAP-related domain. eLife. 2016 Apr 27;5(APRIL2016). e14713. https://doi.org/10.7554/eLife.14713
He, Shuning ; Mansour, Marc R. ; Zimmerman, Mark W. ; Ki, Dong Hyuk ; Layden, Hillary M. ; Akahane, Koshi ; Gjini, Evisa ; de Groh, Eric D. ; Perez-Atayde, Antonio R. ; Zhu, Shizhen ; Epstein, Jonathan A. ; Thomas Look, A. / Synergy between loss of NF1 and overexpression of MYCN in neuroblastoma is mediated by the GAP-related domain. In: eLife. 2016 ; Vol. 5, No. APRIL2016.
@article{854136b0e6fe49b1860c141ca4ee0a32,
title = "Synergy between loss of NF1 and overexpression of MYCN in neuroblastoma is mediated by the GAP-related domain",
abstract = "Earlier reports showed that hyperplasia of sympathoadrenal cell precursors during embryogenesis in Nf1-deficient mice is independent of Nf1‘s role in down-modulating RAS-MAPK signaling. We demonstrate in zebrafish that nf1 loss leads to aberrant activation of RAS signaling in MYCN-induced neuroblastomas that arise in these precursors, and that the GTPase-activating protein (GAP)-related domain (GRD) is sufficient to suppress the acceleration of neuroblastoma in nf1-deficient fish, but not the hypertrophy of sympathoadrenal cells in nf1 mutant embryos. Thus, even though neuroblastoma is a classical {"}developmental tumor{"}, NF1 relies on a very different mechanism to suppress malignant transformation than it does to modulate normal neural crest cell growth. We also show marked synergy in tumor cell killing between MEK inhibitors (trametinib) and retinoids (isotretinoin) in primary nf1a-/- zebrafish neuroblastomas. Thus, our model system has considerable translational potential for investigating new strategies to improve the treatment of very high-risk neuroblastomas with aberrant RAS-MAPK activation.",
author = "Shuning He and Mansour, {Marc R.} and Zimmerman, {Mark W.} and Ki, {Dong Hyuk} and Layden, {Hillary M.} and Koshi Akahane and Evisa Gjini and {de Groh}, {Eric D.} and Perez-Atayde, {Antonio R.} and Shizhen Zhu and Epstein, {Jonathan A.} and {Thomas Look}, A.",
year = "2016",
month = "4",
day = "27",
doi = "10.7554/eLife.14713",
language = "English (US)",
volume = "5",
journal = "eLife",
issn = "2050-084X",
publisher = "eLife Sciences Publications",
number = "APRIL2016",

}

TY - JOUR

T1 - Synergy between loss of NF1 and overexpression of MYCN in neuroblastoma is mediated by the GAP-related domain

AU - He, Shuning

AU - Mansour, Marc R.

AU - Zimmerman, Mark W.

AU - Ki, Dong Hyuk

AU - Layden, Hillary M.

AU - Akahane, Koshi

AU - Gjini, Evisa

AU - de Groh, Eric D.

AU - Perez-Atayde, Antonio R.

AU - Zhu, Shizhen

AU - Epstein, Jonathan A.

AU - Thomas Look, A.

PY - 2016/4/27

Y1 - 2016/4/27

N2 - Earlier reports showed that hyperplasia of sympathoadrenal cell precursors during embryogenesis in Nf1-deficient mice is independent of Nf1‘s role in down-modulating RAS-MAPK signaling. We demonstrate in zebrafish that nf1 loss leads to aberrant activation of RAS signaling in MYCN-induced neuroblastomas that arise in these precursors, and that the GTPase-activating protein (GAP)-related domain (GRD) is sufficient to suppress the acceleration of neuroblastoma in nf1-deficient fish, but not the hypertrophy of sympathoadrenal cells in nf1 mutant embryos. Thus, even though neuroblastoma is a classical "developmental tumor", NF1 relies on a very different mechanism to suppress malignant transformation than it does to modulate normal neural crest cell growth. We also show marked synergy in tumor cell killing between MEK inhibitors (trametinib) and retinoids (isotretinoin) in primary nf1a-/- zebrafish neuroblastomas. Thus, our model system has considerable translational potential for investigating new strategies to improve the treatment of very high-risk neuroblastomas with aberrant RAS-MAPK activation.

AB - Earlier reports showed that hyperplasia of sympathoadrenal cell precursors during embryogenesis in Nf1-deficient mice is independent of Nf1‘s role in down-modulating RAS-MAPK signaling. We demonstrate in zebrafish that nf1 loss leads to aberrant activation of RAS signaling in MYCN-induced neuroblastomas that arise in these precursors, and that the GTPase-activating protein (GAP)-related domain (GRD) is sufficient to suppress the acceleration of neuroblastoma in nf1-deficient fish, but not the hypertrophy of sympathoadrenal cells in nf1 mutant embryos. Thus, even though neuroblastoma is a classical "developmental tumor", NF1 relies on a very different mechanism to suppress malignant transformation than it does to modulate normal neural crest cell growth. We also show marked synergy in tumor cell killing between MEK inhibitors (trametinib) and retinoids (isotretinoin) in primary nf1a-/- zebrafish neuroblastomas. Thus, our model system has considerable translational potential for investigating new strategies to improve the treatment of very high-risk neuroblastomas with aberrant RAS-MAPK activation.

UR - http://www.scopus.com/inward/record.url?scp=84979523801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979523801&partnerID=8YFLogxK

U2 - 10.7554/eLife.14713

DO - 10.7554/eLife.14713

M3 - Article

C2 - 27130733

AN - SCOPUS:84979523801

VL - 5

JO - eLife

JF - eLife

SN - 2050-084X

IS - APRIL2016

M1 - e14713

ER -